Becton Dickinson Tops Estimates With Adjusted EPS of $4.15, Revenue of $5.27 Billion
The company issued fiscal 2027 adjusted EPS guidance of $13.10 to $13.30 and low single-digit revenue growth.
Becton Dickinson BDX
Becton Dickinson & Co · NYSE · Surgical & Medical Instruments & Apparatus
$209.19+5.56%close on Nov. 4, 2026 · volume 4.5M · Yahoo Finance
Price, last 52 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sold 10b5-1 plan | 76 | $198.13 | $15,058 |
| Sept. 28, 2026 | Michael Feld EVP, Chief Revenue Officer | Sold 10b5-1 plan | 76 | $183.70 | $13,961 |
| Aug. 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sold 10b5-1 plan | 165 | $188.49 | $31,101 |
| Aug. 13, 2026 | Thomas E. Polen Jr Chairman, CEO and President, director | Sold 10b5-1 plan | 4,152 | $185.00 | $768,120 |
| Aug. 11, 2026 | Roland Goette EVP and President, EMEA | Sold | 2,438 | $180.84 | $440,888 |
| July 27, 2026 | Michael Feld EVP, Chief Revenue Officer | Sold 10b5-1 plan | 75 | $157.13 | $11,785 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 15 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedBD Q4 adjusted EPS of $4.15 beats $4.07 consensus on $5.27 billion revenue, but FY27 adjusted EPS guidance of $13.10 to $13.30 has a $13.20 midpoint below the $13.30 consensus